Cell Membrane-based Biomimetic Nanosystems for Advanced Drug Delivery in Cancer Therapy: A Comprehensive Review
Overview
Affiliations
Natural types of cells display distinct characteristics with homotypic targeting and extended circulation in the blood, which are worthy of being explored as promising drug delivery systems (DDSs) for cancer therapy. To enhance their delivery efficiency, these cells can be combined with therapeutic agents and artificial nanocarriers to construct the next generation of DDSs in the form of biomimetic nanomedicines. In this review, we present the recent advances in cell membrane-based DDSs (CDDSs) and their applications for efficient cancer therapy. Different sources of cell membranes are discussed, mainly including red blood cells (RBC), leukocytes, cancer cells, stem cells and hybrid cells. Moreover, the extraction methods used for obtaining such cells and the mechanism contributing to the functional action of these biomimetic CDDSs are explained. Finally, a future perspective is proposed to highlight the limitations of CDDSs and the possible resolutions toward clinical transformation of currently developed biomimetic chemotherapies.
Skalickova M, Hadrava Vanova K, Uher O, Leischner Fialova J, Petrlakova K, Masarik M Front Immunol. 2025; 15:1479483.
PMID: 39850897 PMC: 11754201. DOI: 10.3389/fimmu.2024.1479483.
Bai S, Wang Z, Zhang Y, Yang Y, Wei Y, Luo Y Theranostics. 2025; 15(1):86-102.
PMID: 39744235 PMC: 11667238. DOI: 10.7150/thno.99481.
Shen H, Ouyang Y, Zhang L, Li J, Wang S Nanomaterials (Basel). 2024; 14(21).
PMID: 39513837 PMC: 11548044. DOI: 10.3390/nano14211757.
Liu Y, Yu S, Chen Y, Hu Z, Fan L, Liang G Front Pharmacol. 2024; 15:1376955.
PMID: 38689664 PMC: 11059051. DOI: 10.3389/fphar.2024.1376955.
Moving beyond traditional therapies: the role of nanomedicines in lung cancer.
Zhang J, Li Y, Guo S, Zhang W, Fang B, Wang S Front Pharmacol. 2024; 15:1363346.
PMID: 38389925 PMC: 10883231. DOI: 10.3389/fphar.2024.1363346.